Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03571256 · ClinicalTrials.gov registry record · Phase 3
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
A Phase 3 study of Tourette Syndrome, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT03571256 is a Phase 3 study of Tourette Syndrome that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 158 participants, above the 82-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (93% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03571256, a Phase 3 study of Tourette Syndrome, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
Standard placebo-controlled, double-blind study design (TEV-50717 \[low dose and high dose\] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TEV-50717
Study Locations (20)
Florida
- Teva Investigational Site 060-0160 - Gainesville
- Teva Investigational Site 060-0166 - Gulf Breeze
- Teva Investigational Site 060-0161 - Miami
- Teva Investigational Site 060-0151 - Orlando
- Teva Investigational Site 060-0153 - Orlando
Illinois
- Teva Investigational Site 060-0155 - Chicago
- Teva Investigational Site 060-0164 - Chicago
Tennessee
- Teva Investigational Site 060-0157 - Memphis
- Teva Investigational Site 060-0156 - Nashville
Georgia
- Teva Investigational Site 060-0168 - Atlanta
Indiana
- Teva Investigational Site 060-0152 - Indianapolis
Kentucky
- Teva Investigational Site 060-0158 - Louisville
Maryland
- Teva Investigational Site 060-0167 - Rockville
Michigan
- Teva Investigational Site 060-0165 - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2018-05-31 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03571256
The ClinicalTrials.gov registry entry for NCT03571256 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (93% higher). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tourette Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03571256 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03571256 about?
NCT03571256 is a clinical study titled "A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)". Standard placebo-controlled, double-blind study design (TEV-50717 \[low dose and high dose\] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.
What is the current status of trial NCT03571256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2018-05-31. Estimated completion is 2019-12-09.
What conditions does trial NCT03571256 study?
This clinical trial studies the following conditions: Tourette Syndrome.
What interventions are being tested in trial NCT03571256?
The interventions under investigation include: Placebo (DRUG), TEV-50717 (DRUG).
Who is sponsoring clinical trial NCT03571256?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03571256 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
ACTIVE NOT RECRUITING · Phase 3
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Sensory Symptoms in Tourette Syndrome
RECRUITING
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.